Latest News for: ceacam5

Edit

Presentation - AACR NCI EORTC 2025 Discovery of AN4035 - CEACAM5 Targeting ADC armed with Proprietary Pan-RAS ON Inhibitor Payload designed to broaden the therapeutic window (Adlai Nortye Ltd)

Public Technologies 27 Oct 2025
A Novel CEACAM5-Targeting Antibody Drug Conjugate (ADC) Armed with a Proprietary Pan-RAS(ON) Inhibitor Payload, Designed to Broaden the Therapeutic Window ... CEACAM5 ... compared to CEACAM5 Top1-based ADC ... CEACAM5 mRNA nTPM ... SK-CO-1 (CEACAM5+) ... CEACAM5.
Edit

AACR-NCI-EORTC PresentationDiscovery of AN4035 - CEACAM5 Targeting ADC Armed with Proprietary Pan-RAS(ON) Inhibitor Payload, Designed to Broaden the Therapeutic Window (Adlai Nortye Ltd)

Public Technologies 27 Oct 2025
) Discovery of AN4035. A Novel CEACAM5-Targeting Antibody Drug Conjugate (ADC) Armed with a Proprietary Pan-RAS(ON) Inhibitor Payload, Designed to Broaden the Therapeutic Window ... Adlai Nortye Ltd. Disclosure Information. Archie Tse MD PhD ... ANL) ... • ... CEACAM5.
Edit

AACR-NCI-EORTC PosterDiscovery of AN4035 - CEACAM5 Targeting ADC Armed with Proprietary Pan-RAS(ON) Inhibitor Payload, Designed to Broaden the Therapeutic Window (Adlai Nortye Ltd)

Public Technologies 27 Oct 2025
This led to the discovery of AN4035, a CEACAM5-directed ADC, leveraging CEACAM5's high expression in RAS-driven malignancies (e.g., colorectal, pancreatic, lung that frequently harbor RAS mutations).
Edit

Poster - AACR NCI EORTC 2025 - Discovery of AN4035 - CEACAM5 Targeting ADC armed with Proprietary Pan-RAS ON Inhibitor Payload designed to broaden the therapeutic window (Adlai Nortye Ltd)

Public Technologies 27 Oct 2025
This led to the discovery of AN4035, a CEACAM5-directed ADC, leveraging CEACAM5's high expression in RAS-driven malignancies (e.g., colorectal, pancreatic, lung that frequently harbor RAS mutations).
  • 1

Article Search

tools
×
×
×
×